Ivermectin, page-472

Review ofthe Emerging Evidence Demonstrating the Efficacy of Ivermectin in theProphylaxis and Treatment of COVID-19

Pierre Kory, MD, 1,*Gianfranco Umberto Meduri, MD, 2 Joseph Varon, MD, 3 Jose Iglesias, DO, 4 andPaul E. Marik,

MD 5

Author informationCopyright and License information Disclaimer

American Journal of Therapeutics. 2021May-Jun; 28(3): e299–e318.

Publishedonline 2021 Apr 22

Conclusions:

Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductionsin mortality, time to clinical recovery, and time to viral clearance.

Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin. Finally, the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088823/